ANDA 73465, held by Teva Parenteral. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 73465 (Sodium Nitroprusside), held by Teva Parenteral, was first approved by FDA on Mar 30, 1992, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 1992 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Nitroprusside25MG/ML ยท injectable;injection | Sodium Nitroprusside | Discontinued |
| Jun 22, 1992 | Supplement 1Labeling | Approved | None posted |
| Mar 30, 1992 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters